SPECT Radiopharmaceuticals

SPECT Radiopharmaceuticals Market Outlook

The global SPECT radiopharmaceuticals market is poised for significant growth, with an estimated value of approximately USD 5.4 billion in 2023 and a projected compound annual growth rate (CAGR) of around 8.2% from 2025 to 2035. This robust growth can be attributed to the rising prevalence of chronic diseases, increasing advancements in imaging technologies, and a growing emphasis on early diagnosis and treatment. Furthermore, the expanding applications of SPECT in various medical fields, such as oncology and cardiology, are driving demand across healthcare facilities worldwide. With the continuous innovation in radiopharmaceuticals and their applications, the market is expected to experience a surge in investments, ultimately leading to enhanced patient outcomes and healthcare efficiency.

Growth Factor of the Market

Several factors are propelling the growth of the SPECT radiopharmaceuticals market, primarily the increasing incidence of diseases requiring imaging for diagnosis, such as cancer and cardiovascular diseases. As healthcare systems worldwide transition towards more personalized and precise healthcare solutions, the demand for advanced imaging techniques and radiotracers is soaring. Additionally, the technological advancements in the production and development of radiopharmaceuticals, including the use of hybrid imaging technologies such as PET/CT and SPECT/CT, contribute to market expansion. The rising awareness regarding the significance of early disease detection and the growing elderly population, who are more susceptible to chronic diseases, also play a crucial role in pushing market growth. Furthermore, the increase in healthcare expenditure and investments in research and development activities within the pharmaceutical sector are expected to create numerous opportunities in this market.

Key Highlights of the Market

• Estimated market value of USD 5.4 billion in 2023 with a CAGR of 8.2% from 2025 to 2035.
• Rising prevalence of chronic diseases is driving demand for SPECT imaging.
• Technological advancements in radiopharmaceuticals enhance diagnostic accuracy.
• Growing elderly population increases the need for effective diagnostic solutions.
• Increased healthcare expenditure and R&D investments foster innovation in the market.

By Product Type

Technetium-99m:

Technetium-99m stands as the most widely used radiopharmaceutical in SPECT imaging, accounting for a significant share of the market. This radioisotope is favored due to its optimal physical properties, including a suitable half-life and gamma emission characteristics, which facilitate high-quality imaging with minimal radiation exposure to patients. The versatility of Technetium-99m allows its application across a range of diagnostic procedures, including bone scans, myocardial perfusion imaging, and tumor localization. As advances in production techniques improve the availability and cost-effectiveness of Technetium-99m, its dominance in the SPECT radiopharmaceuticals market is likely to continue to grow over the forecast period.

Thallium-201:

Thallium-201 is another critical radiopharmaceutical in the SPECT market, primarily utilized in myocardial perfusion imaging to assess cardiac function and detect coronary artery diseases. Its ability to provide valuable information about myocardial viability and perfusion characteristics makes it indispensable in cardiology applications. Despite being less commonly used than Technetium-99m, Thallium-201's unique properties allow it to play a vital role in specialized imaging procedures. As awareness of its diagnostic capabilities increases, the demand for Thallium-201 in SPECT imaging is anticipated to grow, contributing to overall market expansion.

Iodine-123:

Iodine-123 is primarily utilized in SPECT imaging for thyroid assessments and neurological applications, including the diagnosis of conditions such as Alzheimer's disease and Parkinson's disease. Its favorable half-life and emission characteristics enable effective imaging while minimizing radiation exposure. The increasing prevalence of thyroid-related disorders, along with the rising cases of neurological conditions, is expected to drive the demand for Iodine-123 in SPECT procedures. As healthcare providers seek more comprehensive diagnostic solutions, the significance of Iodine-123 in the SPECT radiopharmaceuticals market is anticipated to elevate.

Gallium-67:

Gallium-67 is primarily employed in detecting certain types of cancers and inflammatory diseases due to its unique properties, which allow it to localize in tumor tissues effectively. While its usage in SPECT imaging is less prevalent compared to other isotopes, it remains critical in specific diagnostic scenarios such as lymphoma and infections. The growing emphasis on early cancer detection and the increasing number of clinical studies evaluating the efficacy of Gallium-67 in various applications contribute to its market potential. With ongoing research focusing on improving its utilization, the role of Gallium-67 in the SPECT radiopharmaceutical market is expected to gain traction.

Others:

This category encompasses a range of lesser-known radiopharmaceuticals utilized in SPECT imaging, such as Indium-111 and Lutetium-177. Although these isotopes currently hold a smaller market share, their applications in niche diagnostics and therapeutic areas are gaining recognition. Companies are investing in developing new formulations and improving production methods for these agents, which could lead to increased usage over time. As the demand for personalized medicine grows, the relevance and application of these alternative radiopharmaceuticals are expected to rise, contributing to the overall market landscape.

By Application

Oncology:

The oncology segment is one of the leading applications for SPECT radiopharmaceuticals, driven by the rising incidence of cancer globally. SPECT imaging plays a pivotal role in the detection, staging, and monitoring of various cancers, enabling clinicians to tailor personalized treatment plans based on accurate imaging results. The growing focus on early diagnosis and the effectiveness of radiopharmaceuticals in assessing treatment responses are propelling the demand within this segment. Additionally, advancements in targeted therapies and the increasing use of SPECT in clinical trials further enhance the growth prospects of oncology applications in the SPECT radiopharmaceuticals market.

Cardiology:

Cardiology is another prominent application for SPECT radiopharmaceuticals, particularly in myocardial perfusion imaging and assessing cardiac function. With cardiovascular diseases being one of the leading causes of morbidity and mortality worldwide, the demand for accurate and efficient imaging solutions is paramount. The utilization of radiopharmaceuticals such as Technetium-99m and Thallium-201 in SPECT allows for detailed evaluation of cardiac health and facilitates timely intervention. As the prevalence of heart diseases rises, so does the need for advanced diagnostic tools, positioning cardiology as a vital segment within the SPECT radiopharmaceuticals market.

Neurology:

The neurology application segment of the SPECT radiopharmaceuticals market has been gaining traction due to the increasing awareness and diagnosis of neurological disorders, including Alzheimer's and Parkinson's disease. SPECT imaging is invaluable in providing insights into cerebral blood flow and metabolic activity, aiding in the accurate diagnosis and management of these conditions. The growing elderly population, along with enhanced access to neurological imaging technologies, contributes to the rising demand for SPECT radiopharmaceuticals in neurology. As research continues to explore the role of imaging in neurological disorders, this segment is expected to experience substantial growth in the coming years.

Thyroid:

The thyroid application segment focuses on the use of SPECT radiopharmaceuticals for diagnosing thyroid-related disorders. Iodine-123 is commonly used for thyroid imaging, enabling healthcare professionals to evaluate thyroid function and detect abnormalities such as nodules and goiters. As the prevalence of thyroid disorders rises, the demand for SPECT imaging solutions in this field is expected to grow. Moreover, the increasing emphasis on personalized medicine and the integration of advanced technologies into diagnostic practices will further bolster the relevance of SPECT radiopharmaceuticals in thyroid applications.

Others:

The "Others" category comprises various niche applications where SPECT radiopharmaceuticals are utilized, including infection imaging and bone disorders. While these applications may not be as mainstream as oncology or cardiology, they play a critical role in specific diagnostic scenarios. The growing understanding of the importance of imaging in managing infections and other diseases is fostering investments and research in this area. As healthcare providers seek comprehensive diagnostic solutions, the demand for SPECT radiopharmaceuticals in these niche applications is anticipated to increase, contributing to the overall growth of the market.

By Distribution Channel

Hospitals:

The hospital segment is the primary distribution channel for SPECT radiopharmaceuticals, accounting for a substantial market share. Hospitals are equipped with advanced imaging technologies and trained personnel to administer SPECT procedures, making them a key player in the distribution chain. The rising number of hospitals incorporating nuclear medicine departments and the growing preference for in-house imaging services are boosting the demand for radiopharmaceuticals in this channel. Furthermore, the increasing patient footfall and the need for comprehensive diagnostic services contribute to the growing utilization of SPECT in hospitals, driving market expansion.

Diagnostic Centers:

Diagnostic centers are emerging as significant players in the distribution of SPECT radiopharmaceuticals, providing specialized imaging services to patients. These centers typically focus on outpatient diagnostics, offering timely access to imaging procedures and consultations. The increasing number of diagnostic centers and their collaboration with hospitals for referral services have positively impacted the demand for SPECT imaging. As patients seek more accessible and cost-effective diagnostic solutions, the role of diagnostic centers in the SPECT radiopharmaceuticals market is expected to grow, further enhancing the market landscape.

Research Institutes:

Research institutes play a vital role in the development and advancement of SPECT radiopharmaceuticals, conducting studies and clinical trials to evaluate new imaging agents and techniques. These institutions often collaborate with pharmaceutical companies and healthcare organizations to optimize the use of SPECT in research applications. The growing emphasis on research and development in the healthcare sector is anticipated to drive demand for SPECT radiopharmaceuticals in research institutes, as they continue to contribute to the advancement of imaging technologies and their applications in various medical fields.

Online Pharmacies:

Online pharmacies are gradually gaining traction in the distribution of SPECT radiopharmaceuticals, providing a convenient option for healthcare facilities to procure these products. The rise of e-commerce platforms in the pharmaceutical industry allows hospitals and diagnostic centers to streamline their procurement processes, reducing lead times and enhancing efficiency. As regulatory frameworks evolve to accommodate online sales of radiopharmaceuticals and the demand for remote healthcare solutions increases, the role of online pharmacies in the distribution channel is expected to expand, creating new opportunities in the market.

Others:

The "Others" category includes various distribution channels such as specialty pharmacies and wholesalers, which also play a role in the SPECT radiopharmaceuticals market. These channels offer targeted services and can help ensure the timely delivery of critical radiopharmaceuticals to healthcare providers. While their market share may be smaller compared to hospitals and diagnostic centers, their contributions are significant for specific target markets and niche applications. As the healthcare landscape continues to evolve, the role of these alternative distribution channels in the SPECT radiopharmaceuticals market may become increasingly relevant.

By Ingredient Type

Single-Photon Emission Computed Tomography (SPECT) Agents:

SPECT agents are the cornerstone of the SPECT radiopharmaceuticals market, enabling advanced imaging techniques and diagnostic capabilities. By providing real-time information on biological processes, these agents assist healthcare professionals in effectively diagnosing and monitoring various diseases. The continued development of novel SPECT agents that target specific physiological mechanisms is expected to drive growth in this segment. Furthermore, the increasing emphasis on personalized medicine and tailored imaging approaches is likely to contribute to the rising demand for innovative SPECT agents, enhancing their market presence.

Radiotracers:

Radiotracers play a crucial role in SPECT imaging by highlighting specific biological processes within the body. Their ability to localize in target tissues allows for enhanced visualization and analysis of various diseases, making them essential for accurate diagnostics. The advancement of radiotracer technology and the introduction of novel agents specifically designed for targeted imaging will likely spur growth in this segment. As healthcare providers increasingly recognize the importance of SPECT in disease diagnosis and treatment, the demand for radiotracers is expected to rise, further solidifying their position in the market.

Others:

The "Others" category includes various niche ingredients used in SPECT radiopharmaceuticals that may not fall into the traditional classifications. These ingredients, while currently holding a smaller market share, are essential for specific applications and research developments. As innovation continues in the field of radiopharmaceuticals, the importance and market presence of these alternative ingredient types are expected to grow. The expansion of research initiatives and the increasing focus on targeted therapies may lead to the emergence of new ingredient categories within the SPECT market, creating additional opportunities for growth.

By Photon Emission Computed Tomography

Planar SPECT:

Planar SPECT techniques have been widely utilized in the medical field for diagnostic imaging, offering valuable insights into various physiological processes. While not as advanced as other imaging modalities, planar SPECT remains essential for specific applications due to its cost-effectiveness and accessibility. This method allows for the acquisition of images that can assist in identifying abnormalities in organs and tissues, providing critical information for patient management. As advancements in imaging technology continue to enhance the capabilities of planar SPECT, its demand is expected to remain steady, contributing to the overall growth of the SPECT radiopharmaceuticals market.

Hybrid SPECT/CT:

The hybrid SPECT/CT imaging modality is gaining traction due to its ability to combine functional imaging with anatomical details, providing a comprehensive view of the patient's condition. This approach enhances the accuracy of diagnoses and allows for better treatment planning, making it invaluable in oncology, cardiology, and neurology. The rising preference for minimally invasive diagnostic techniques and the increasing emphasis on personalized medicine are driving the adoption of hybrid SPECT/CT. As healthcare providers continue to seek advanced imaging solutions, the demand for hybrid SPECT/CT technologies is expected to grow, positively impacting the SPECT radiopharmaceuticals market.

By Region

The North American region currently leads the SPECT radiopharmaceuticals market, primarily due to the presence of advanced healthcare infrastructure, extensive research activities, and rising healthcare expenditures. The United States holds a significant share of the market, attributed to the increasing prevalence of chronic diseases and the growing demand for imaging technologies. As per industry forecasts, the North American market for SPECT radiopharmaceuticals is expected to grow at a CAGR of around 8.5% between 2025 and 2035, reflecting the ongoing advancements in medical imaging and the expansion of diagnostic services.

Europe is another prominent region in the SPECT radiopharmaceuticals market, with countries like Germany, France, and the United Kingdom leading in demand. The region's growth is fueled by the increasing focus on early disease detection, advancements in imaging technologies, and a well-established healthcare system. As European countries prioritize research and development in medical imaging, the SPECT radiopharmaceuticals market is expected to witness substantial growth over the forecast period. The combined market share of Europe and North America is projected to account for approximately 62% of the global SPECT radiopharmaceuticals market by 2035, indicating the significance of these regions in driving market trends.

Opportunities

The SPECT radiopharmaceuticals market presents numerous opportunities for growth and innovation, particularly in the realm of research and development. As the demand for personalized medicine escalates, pharmaceutical companies are being urged to invest in developing novel radiopharmaceuticals that target specific diseases and patient populations. This shift towards more tailored therapeutic approaches opens doors for new products and improved imaging capabilities. Additionally, the integration of artificial intelligence and machine learning technologies into imaging analysis can enhance the accuracy and efficiency of SPECT procedures, creating opportunities for companies to leverage these advancements to differentiate their offerings in the market.

Furthermore, the increasing aging population worldwide is expected to contribute significantly to the demand for SPECT radiopharmaceuticals, as older individuals are more susceptible to chronic diseases that require advanced diagnostic solutions. This demographic shift presents an opportunity for market players to expand their product portfolios and enhance their service offerings to cater to the unique healthcare needs of this population. Moreover, as healthcare systems worldwide continue to focus on improving patient outcomes and operational efficiencies, companies that innovate in SPECT technologies and collaborate with healthcare providers are likely to thrive in this evolving landscape.

Threats

Despite the promising growth prospects in the SPECT radiopharmaceuticals market, several threats could hinder market expansion. One of the primary concerns is the stringent regulatory environment surrounding the approval and use of radiopharmaceuticals. Regulatory bodies impose rigorous testing and compliance requirements, which can prolong the time-to-market for new products and increase development costs. This challenge may limit the entry of new players in the market and inhibit innovation, ultimately affecting the competitive landscape. Additionally, the increasing pressure to reduce healthcare costs may lead healthcare providers to prioritize more cost-effective imaging technologies, potentially impacting the demand for SPECT radiopharmaceuticals.

Another significant threat to the market is the potential for supply chain disruptions, particularly in the production and distribution of radiopharmaceuticals. Factors such as natural disasters, geopolitical tensions, and pandemics can curtail the availability of critical isotopes and hinder their timely delivery to healthcare providers. These disruptions can lead to temporary shortages and affect patient access to essential diagnostic services. Moreover, the growing competition from alternative imaging modalities, such as PET scans and MRI, presents an ongoing challenge within the market, as these technologies may offer similar diagnostic capabilities with added advantages, thereby exerting pressure on the SPECT radiopharmaceuticals market.

Competitor Outlook

• GE Healthcare
• Siemens Healthineers
• Bayer AG
• Bracco Imaging
• Cardinal Health
• Curium Pharma
• Radiopharma Solutions
• NorthStar Medical Radioisotopes
• Advanced Accelerator Applications (AAA)
• Ion Beam Applications (IBA)
• Lantheus Medical Imaging
• Telix Pharmaceuticals
• Eckert & Ziegler Strahlen und Medizintechnik AG
• Novartis
• Fermion

The competitive landscape of the SPECT radiopharmaceuticals market is characterized by a mix of established players and emerging companies striving to capture market share through innovation, strategic partnerships, and geographic expansion. Major companies such as GE Healthcare and Siemens Healthineers dominate the market with their extensive portfolios of imaging technologies and radiopharmaceuticals. These organizations invest significantly in research and development, continually advancing SPECT imaging capabilities and developing new radiopharmaceuticals to address unmet clinical needs. As they enhance their product offerings, these companies maintain a competitive edge and reinforce their positions as market leaders.

In addition to established players, several emerging companies are entering the SPECT radiopharmaceuticals market, focusing on niche products and specialized applications. Organizations like Curium Pharma and NorthStar Medical Radioisotopes are showcasing innovative approaches to manufacturing and distributing radiopharmaceuticals, thereby enhancing accessibility for healthcare providers. These emerging companies are increasingly investing in research collaborations and acquisitions to strengthen their market position and expand their product portfolios. As competition intensifies, these players will need to differentiate themselves through unique product offerings and high-quality services.

Furthermore, strategic collaborations and partnerships play a critical role in shaping the competitive landscape of the SPECT radiopharmaceuticals market. Companies are increasingly engaging in strategic alliances with research institutions, technology providers, and healthcare organizations to foster innovation and streamline the development of new imaging agents. These collaborations not only enhance product development capabilities but also facilitate the entry into new markets and regions. Through such strategic efforts, companies can leverage complementary strengths to drive growth and establish a more prominent presence in the ever-evolving SPECT radiopharmaceuticals market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Fermion
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Bayer AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Curium Pharma
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 GE Healthcare
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Bracco Imaging
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Cardinal Health
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Siemens Healthineers
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Radiopharma Solutions
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Telix Pharmaceuticals
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Lantheus Medical Imaging
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Ion Beam Applications (IBA)
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 NorthStar Medical Radioisotopes
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Advanced Accelerator Applications (AAA)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Eckert & Ziegler Strahlen und Medizintechnik AG
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 SPECT Radiopharmaceuticals Market, By Application
    • 6.1.1 Oncology
    • 6.1.2 Cardiology
    • 6.1.3 Neurology
    • 6.1.4 Thyroid
    • 6.1.5 Others
  • 6.2 SPECT Radiopharmaceuticals Market, By Product Type
    • 6.2.1 Technetium-99m
    • 6.2.2 Thallium-201
    • 6.2.3 Iodine-123
    • 6.2.4 Gallium-67
    • 6.2.5 Others
  • 6.3 SPECT Radiopharmaceuticals Market, By Ingredient Type
    • 6.3.1 Single-Photon Emission Computed Tomography (SPECT) Agents
    • 6.3.2 Radiotracers
    • 6.3.3 Others
  • 6.4 SPECT Radiopharmaceuticals Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Diagnostic Centers
    • 6.4.3 Research Institutes
    • 6.4.4 Online Pharmacies
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 SPECT Radiopharmaceuticals Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global SPECT Radiopharmaceuticals market is categorized based on

By Product Type

• Technetium-99m
• Thallium-201
• Iodine-123
• Gallium-67
• Others

By Application

• Oncology
• Cardiology
• Neurology
• Thyroid
• Others

By Distribution Channel

• Hospitals
• Diagnostic Centers
• Research Institutes
• Online Pharmacies
• Others

By Ingredient Type

• Single-Photon Emission Computed Tomography (SPECT) Agents
• Radiotracers
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• GE Healthcare
• Siemens Healthineers
• Bayer AG
• Bracco Imaging
• Cardinal Health
• Curium Pharma
• Radiopharma Solutions
• NorthStar Medical Radioisotopes
• Advanced Accelerator Applications (AAA)
• Ion Beam Applications (IBA)
• Lantheus Medical Imaging
• Telix Pharmaceuticals
• Eckert & Ziegler Strahlen und Medizintechnik AG
• Novartis
• Fermion